Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of allogeneic umbilical cord mesenchymal stem cells in preterm infants with bronchopulmonary dysplasia
2022-002653-26Phase 2Active
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Start
- Jan 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic umbilical cord-derived mesenchymal stem cells in bronchopulmonary dysplasia (BPD), sponsored by Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal. Primary endpoint: Safety assessment. Started Jan 2023; status: active.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2022-002653-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002653-26.